Luke C Pilling
Overview
Explore the profile of Luke C Pilling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
4039
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murrin O, Mounier N, Voller B, Tata L, Gallego-Moll C, Roso-Llorach A, et al.
EBioMedicine
. 2025 Feb;
113:105584.
PMID: 39919332
Background: Multimorbidity, the presence of two or more conditions in one person, is common but studies are often limited to observational data and single datasets. We address this gap by...
2.
Walker K, An Y, Moghekar A, Moaddel R, Duggan M, Peng Z, et al.
Mol Neurodegener
. 2024 Nov;
19(1):81.
PMID: 39482741
Background: Apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late onset Alzheimer's disease (AD). This case-cohort study used targeted plasma biomarkers and large-scale proteomics to examine...
3.
Tian Q, Zweibaum D, Qian Y, Oppong R, Pilling L, Casanova F, et al.
Geroscience
. 2024 Sep;
47(1):825-835.
PMID: 39313624
Mitochondrial dysfunction is linked to physical impairment and dementia. Mitochondrial DNA copy number (mtDNAcn) from blood may predict cognitive decline and dementia risk, but the effect of somatic mutations or...
4.
Lucas M, Pilling L, Atkins J, Melzer D
Hepatology
. 2024 Aug;
PMID: 39178373
Background Aims: The HFE p.C282Y+/+ (homozygous) genotype and central adiposity both increase liver disease and diabetes risks, but combined effects are unclear. We estimated waist-to-hip ratio (WHR) associations with incident...
5.
Kuo C, Liu P, Drouard G, Vuoksimaa E, Kaprio J, Ollikainen M, et al.
medRxiv
. 2024 Jul;
PMID: 38978645
The focus of aging research has shifted from increasing lifespan to enhancing healthspan to reduce the time spent living with disability. Despite significant efforts to develop biomarkers of aging, few...
6.
Casanova F, Tian Q, Williamson D, Qian Y, Zweibaum D, Ding J, et al.
Neurobiol Dis
. 2024 May;
197:106539.
PMID: 38789058
Background: Iron overload is observed in neurodegenerative diseases, especially Alzheimer's disease (AD) and Parkinson's disease (PD). Homozygotes for the iron-overload (haemochromatosis) causing HFE p.C282Y variant have increased risk of dementia...
7.
Kuo C, Chen Z, Liu P, Pilling L, Atkins J, Fortinsky R, et al.
Aging Cell
. 2024 May;
23(8):e14195.
PMID: 38747160
Beyond mere prognostication, optimal biomarkers of aging provide insights into qualitative and quantitative features of biological aging and might, therefore, offer useful information for the testing and, ultimately, clinical use...
8.
Turkmen D, Bowden J, Masoli J, Melzer D, Pilling L
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38674010
The solute carrier organic anion transporter family member 1B1 () encodes the organic anion-transporting polypeptide 1B1 (OATP1B1 protein) that transports statins to liver cells. Common genetic variants in , such...
9.
Turkmen D, Bowden J, Masoli J, Delgado J, Kuo C, Melzer D, et al.
Pharmacogenomics J
. 2024 Apr;
24(3):12.
PMID: 38632276
Pharmacogenetic variants are associated with clinical outcomes during Calcium Channel Blocker (CCB) treatment, yet whether the effects are modified by genetically predicted clinical risk factors is unknown. We analyzed 32,000...
10.
Lucas M, Atkins J, Pilling L, Shearman J, Melzer D
BMJ Open
. 2024 Mar;
14(3):e081926.
PMID: 38479735
Objectives: haemochromatosis genetic variants have an uncertain clinical penetrance, especially to older ages and in undiagnosed groups. We estimated p.C282Y and p.H63D variant cumulative incidence of multiple clinical outcomes in...